57% of patients achieved responder status at one year in the open-label extension (OLE) study. Responder status is defined by maintaining normal serum calcium levels and independence from conventional therapy (active vitamin D and >600 mg/day of calcium). Pharmacokinetic data confirms the viability of once-weekly dosing with a peak-to-trough ratio of approximately 1.3. Clinical markers showed restoration of physiologic PTH activity, including improved kidney function (eGFR) and normalized bone turnover. The study maintained a 90% patient retention rate through the one-year mark.